190 related articles for article (PubMed ID: 25521528)
1. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
[TBL] [Abstract][Full Text] [Related]
2. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Am J Hematol; 2015 Aug; 90(8):696-701. PubMed ID: 25963924
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
[TBL] [Abstract][Full Text] [Related]
5. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Castillo JJ; Olszewski AJ; Hunter ZR; Kanan S; Meid K; Treon SP
Cancer; 2015 Jul; 121(13):2230-6. PubMed ID: 25757851
[TBL] [Abstract][Full Text] [Related]
6. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
[TBL] [Abstract][Full Text] [Related]
7. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
[TBL] [Abstract][Full Text] [Related]
8. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes.
Vos JM; Gustine J; Rennke HG; Hunter Z; Manning RJ; Dubeau TE; Meid K; Minnema MC; Kersten MJ; Treon SP; Castillo JJ
Br J Haematol; 2016 Nov; 175(4):623-630. PubMed ID: 27468978
[TBL] [Abstract][Full Text] [Related]
9. Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.
Jeong S; Kong SG; Kim DJ; Lee S; Lee HS
BMC Cancer; 2020 Jul; 20(1):623. PubMed ID: 32620091
[TBL] [Abstract][Full Text] [Related]
10. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N
J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570
[TBL] [Abstract][Full Text] [Related]
12. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
[TBL] [Abstract][Full Text] [Related]
13. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
[TBL] [Abstract][Full Text] [Related]
14. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
[TBL] [Abstract][Full Text] [Related]
15. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
16. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
17. The incidence and survival of Waldenström's Macroglobulinaemia in South East England.
Phekoo KJ; Jack RH; Davies E; Møller H; Schey SA;
Leuk Res; 2008 Jan; 32(1):55-9. PubMed ID: 17416416
[TBL] [Abstract][Full Text] [Related]
18. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
Amaador K; Kersten MJ; Visser O; Brink M; Posthuma EFM; Minnema MC; Vos JMI; Dinmohamed AG
Br J Haematol; 2022 Feb; 196(3):660-669. PubMed ID: 34605017
[TBL] [Abstract][Full Text] [Related]
19. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.
Saito A; Isoda A; Kojima M; Yokohama A; Tsukune Y; Sasaki M; Ito S; Ohtsu A; Koike M; Murayama K; Moriya K; Tamura H; Matsumoto M; Nakahashi H; Tanosaki S; Sakura T; Kawamura T; Miyanaga T; Nakamura N; Murakami H; Handa H; Tsukamoto N
Int J Hematol; 2017 Nov; 106(5):681-690. PubMed ID: 28687991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
